TFAM and neoplasm: By integrating phenotypic assays with transcriptomic profiling, distinct downstream effectors were revealed—including TRAF2 and LOXL2—that connect TFAM dysregulation to cell cycle control, metabolic reprogramming, and tumor invasiveness.